Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
2014 2
2018 3
2020 1
2021 1
2022 6
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
[Multiple injuries].
Kafi H, Asai S, Noguchi T, Oka H, Harima K. Kafi H, et al. Kango Gijutsu. 1980 Jul;26(9):1266-71. Kango Gijutsu. 1980. PMID: 6901846 Japanese. No abstract available.
A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.
Nodehi RS, Kalantari B, Raafat J, Ansarinejad N, Moazed V, Mortazavizadeh SMR, Hosseinzadeh M, Ghaderi B, Jenabian A, Qadyani M, Haghighat S, Allahyari A, Mirzania M, Seghatoleslami M, Payandeh M, Alikhasi A, Kafi H, Shahi F. Nodehi RS, et al. Among authors: kafi h. BMC Pharmacol Toxicol. 2022 Jul 28;23(1):57. doi: 10.1186/s40360-022-00599-x. BMC Pharmacol Toxicol. 2022. PMID: 35902898 Free PMC article. Clinical Trial.
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, Bary A, Mirzania M, Haghighat S, Razavi SM, Emami SAH, Hosseinzadeh M, Mirbolouk M, Sadighi S, Shahrasbi A, Esfahani A, Gity M, Anjidani N, Kafi H, Najafi S. Allahyari A, et al. Among authors: kafi h. BMC Cancer. 2022 Sep 7;22(1):960. doi: 10.1186/s12885-022-09895-5. BMC Cancer. 2022. PMID: 36071409 Free PMC article. Clinical Trial.
Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.
Nafar M, Mostafaloo N, Firouzan A, Poorrezagholi F, Samadian F, Dalili N, Barati S, Anjidani N, Kafi H, Shahpari R, Bayat M, Kianipour S, Samavat S. Nafar M, et al. Among authors: kafi h. Clin Ther. 2022 Dec;44(12):1566-1576. doi: 10.1016/j.clinthera.2022.10.002. Epub 2022 Oct 24. Clin Ther. 2022. PMID: 36402595 Free PMC article. Clinical Trial.
Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.
Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, Kafi H, Fallah N, Ebrahimi A, Taheri A, Petrovsky N, Barati S. Tabarsi P, et al. Among authors: kafi h. Clin Microbiol Infect. 2023 Feb;29(2):215-220. doi: 10.1016/j.cmi.2022.09.001. Epub 2022 Sep 10. Clin Microbiol Infect. 2023. PMID: 36096430 Free PMC article. Clinical Trial.
Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study.
Jenabian A, Ehsanpour A, Mortazavizadeh SMR, Raafat J, Razavi M, Khosravi A, Seifi S, Salimi B, Anjidani N, Kafi H. Jenabian A, et al. Among authors: kafi h. Support Care Cancer. 2022 Oct;30(10):8151-8158. doi: 10.1007/s00520-022-07265-2. Epub 2022 Jul 6. Support Care Cancer. 2022. PMID: 35792924
22 results